- Home
- ANIX vs OVID Comparison
ANIX vs OVID Comparison
Compare ANIX & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- OVID
- Stock Information
- Founded
- ANIX 1982
- OVID 2014
- Country
- ANIX United States
- OVID United States
- Employees
- ANIX N/A
- OVID N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- OVID Health Care
- Exchange
- ANIX Nasdaq
- OVID Nasdaq
- Market Cap
- ANIX 95.7M
- OVID 88.9M
- IPO Year
- ANIX 1987
- OVID 2017
- Fundamental
- Price
- ANIX $4.90
- OVID $1.79
- Analyst Decision
- ANIX Strong Buy
- OVID Strong Buy
- Analyst Count
- ANIX 3
- OVID 4
- Target Price
- ANIX $9.00
- OVID $3.13
- AVG Volume (30 Days)
- ANIX 216.1K
- OVID 5.1M
- Earning Date
- ANIX 09-10-2025
- OVID 11-11-2025
- Dividend Yield
- ANIX N/A
- OVID N/A
- EPS Growth
- ANIX N/A
- OVID N/A
- EPS
- ANIX N/A
- OVID N/A
- Revenue
- ANIX N/A
- OVID $6,651,000.00
- Revenue This Year
- ANIX N/A
- OVID $1,086.57
- Revenue Next Year
- ANIX N/A
- OVID N/A
- P/E Ratio
- ANIX N/A
- OVID N/A
- Revenue Growth
- ANIX N/A
- OVID 1070.95
- 52 Week Low
- ANIX $2.07
- OVID $0.24
- 52 Week High
- ANIX $4.49
- OVID $2.01
- Technical
- Relative Strength Index (RSI)
- ANIX 81.97
- OVID 63.70
- Support Level
- ANIX $3.21
- OVID $1.57
- Resistance Level
- ANIX $3.44
- OVID $2.01
- Average True Range (ATR)
- ANIX 0.21
- OVID 0.21
- MACD
- ANIX 0.13
- OVID 0.02
- Stochastic Oscillator
- ANIX 99.48
- OVID 74.39
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.